500,000 More Mpox Vaccinations

The U.S. Department of Health and Human Services (HHS), through the Administration for Strategic Preparedness and Response, announced today it is taking action to increase the supply of mpox vaccines.

This news supports the U.S. Government's commitment to making over 1 million combined doses of Bavarian Nordic A/S JYNNEOS® (MVA-BN®) vaccines available to the global mpox response focused in Africa.

Since JYNNEOS is a two-dose vaccination regimen, this announcement indicates about 500,000 individuals can be vaccinated.

“A public health threat to one is a public health threat to all. HHS is committed to fighting the current mpox outbreak, including through this vaccine donation. Disease doesn’t respect borders, and it is our duty to work together to make our world healthier. Our partnerships across the globe in fighting infectious disease will help keep us safe,” said HHS Secretary Xavier Becerra in a press release on September 24, 2024.

According to HHS, these vaccine efforts build on the $1.94 billion invested in funds and technical expertise to develop and sustain JYNNEOS, which is FDA-approved for both mpox and smallpox. The product would not exist without the investment and technical expertise the U.S. government provided.

More information on the U.S. response to the Clade 1 mpox outbreak can be found on the HHS mpox response website. JYNNEOS's efficacy against the Clade 1 mpox virus remains under investigation.